Phytopharm's Cogane has comprehensively failed the Phase II CONFIDENT-PD trial for the treatment of early stage Parkinson's disease patients.
Phytopharm's Cogane has comprehensively failed the Phase II CONFIDENT-PD trial for the treatment of early stage Parkinson's disease patients.
Cogane had no beneficial effects on patients' symptoms measured by the primary or secondary endpoints at any of the three...
Create an account to read this article
Already a subscriber?
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.
A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.
The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.
The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.
